Eli Lilly and Co LLYHospitals and medical services
9.72 % of fund value
Diabetes and weight-loss drugs
SCB GLOBAL HEALTH CARE EQUITY FUND
Shows where this fund stands in its group. Not investment advice · Data as of 3 Nov 2026
SCBGHCA invests through the master fund Janus Henderson Global Life Sciences Fund 101.16%
This fundSCBGHCA
The fund that actually investsJanus Henderson Global Life Sciences FundThis fund and the master fund each charge their own fees. See the fees section of this page for the actual fees
Eli Lilly and Co LLY9.72%
Johnson & Johnson JNJ7.87%
ABBVIE ABBV4.99%
Unitedhealth Group UNH4.32%
AstraZeneca AZN.L3.75%
Thermo Fisher TMO3.39%
Novartis NOVN2.76%
Roche ROG2.71%
argenx ARGX2.48%
Merck & MRK2.38%Eli Lilly and Co LLYDiabetes and weight-loss drugs
An American medicines and medical devices company, with products such as cancer drugs and surgical instruments
ABBVIE ABBVHospitals, medicines and medical equipment
Hospitals, medicines and medical equipment
AstraZeneca AZN.LHospitals, medicines and medical equipment
Thermo Fisher TMOAn American company selling scientific instruments, reagents and services for laboratories
Novartis NOVNHospitals, medicines and medical equipment
Roche ROGHospitals, medicines and medical equipment
argenx ARGXEuropean biotech that makes Vyvgart to treat autoimmune diseases such as myasthenia gravis
Merck & MRKHospitals, medicines and medical equipment
Based on the master fund's share of this fund's value (101.16% as of 31 Jul 2026) × each stock's weight in the master fund · stocks as of 30 Sep 2026 · fact sheet from Janus Henderson · Illustrations are for explanation only, not individual stock recommendations
Data as of 30 Sep 2026 · Top 6 shown, the rest grouped as Other · per Janus Henderson fact sheet
Over the past year it beat half its group; over 5 years it returned +3.38% per year (Top 25% of the group)
No. 1 is SCBGENOME(E) +62.13%
No. 1 is SCBGENOME(E) +21.97% per year
No. 1 is FP HCARE-A +6.61% per year
Each bar is one fund in the AIMC Health Care group, sorted from highest to lowest return · Every share class is counted, and only funds with a full track record for the period are included · Calculated from NAV as of 3 Nov 2026
Past performance is not a guarantee of future results
| YTD | 1W | 2W | 1M | 3M | 6M | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|---|
| +9.95% | +2.75% | +5.09% | +7.14% | +4.37% | +13.81% | +19.12% | +42.69% | +18.05% | +24.38% |
Total return over each period, matching the NAV chart periods · Not annualised
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Full year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.1 | +1.8 | −6.4 | +1.3 | +1.8 | +8.1 | −0.9 | +3.3 | −4.4 | +6.4 | −0.7 | · | +9.9* |
| 2025 | +5.2 | −0.4 | −4.8 | −0.9 | −5.9 | +1.7 | −1.2 | +5.5 | +2.2 | +8.3 | +8.9 | −0.5 | +18.3 |
| 2024 | +2.1 | +3.5 | +1.5 | −5.1 | +3.1 | +2.8 | +1.9 | +4.1 | −3.0 | −3.2 | −0.8 | −7.9 | −1.9 |
| 2023 | −0.2 | −4.2 | +1.9 | +3.5 | −2.8 | +2.8 | +0.3 | −1.8 | −4.2 | −7.0 | +6.7 | +7.0 | +1.0 |
| 2022 | −9.3 | +0.3 | +3.4 | −6.8 | −1.2 | −0.8 | +4.2 | −3.4 | −3.2 | +8.2 | +4.9 | −1.4 | −6.3 |
Largest drawdown in the selected period −23.23% Previous peak 3 Nov 2021 (NAV 13.6270) → Trough 16 Jun 2022 (NAV 10.4609) · Back to the previous peak on 10 Jul 2024, after 2 years
Currently −2.69% from the peak NAV of 16.3826 (19 Aug 2026)
Over 5 years, SCBGHCA returned 0.20 per unit of volatility, ranking 4 of 33 funds · The highest is FP HCARE-A (0.43)
กองทุนมีนโยบายเน้นลงทุนในหน่วยลงทุนของกองทุนรวมต่างประเทศเพียงกองทุนเดียว (Feeder Fund) ได้แก่ Janus Henderson Global Life Sciences Fund (กองทุนหลัก) ชนิดหน่วยลงทุน (share class) I acc สกุลเงินดอลลาร์สหรัฐ (USD) กองทุนหลักบริหารโดย Henderson Management S.A.จดทะเบียนภายใต้กฎหมายของประเทศไอร์แลนด… Its largest holdings are หน่วยลงทุน JANUS HENDERSON GLOBAL LIFE SCIENCES FUND 100.51% (fact sheet 31 Aug 2026)
Risk level 7 of 8 (High risk). Since 11 Aug 2021, its NAV has fallen as much as −23.23% from its peak.
Actual total expense ratio (TER) 1.72% a year, against a ceiling of 2.90%. Management fee 1.61%. Front-end fee 1.61%. Back-end fee 0.00%. (Fact sheet 31 Jul 2026)
No. Gains or losses accumulate in the NAV, and investors receive their return when they redeem units
Minimum first purchase 1 THB, subsequent purchases 1 THB. Buy orders accepted until 15:30, sell orders until 15:30, and redemption proceeds are paid T+5
Almost fully hedged. As of 31 Jul 2026, 100.09% of the value of its foreign investments was hedged
They are share classes of the same fund and invest in the same assets. They differ only in each class's terms, such as dividend policy, fees or who can buy · SCBGHCA: no dividends, TER 1.72% · SCBGHC: pays dividends, TER 1.72% · SCBGHCE: see the conditions in the prospectus · SCBGHCP: see the conditions in the prospectus · SCBGHCR: see the conditions in the prospectus
Past performance is not a guarantee of future results · Investing involves risk. Investors should understand the product's features, return conditions and risks before making an investment decision · This fund invests abroad, so investors may lose or gain from exchange rate movements